Standard doxorubicin-based combination chemotherapy, such as CHOP, frequently induces remissions of short duration. The overall CR rate is 915 and induction-therapy mortality was low (6%). In one review the estimated 5-year CR rate was 38% and the estimated 5-year survival rate was 39%. These results were achieved despite broad entrance criteria (no exclusions by age, performance status, organ dysfunction, or infection status at the time of diagnosis). Median age was 39.5 years, about 10 years higher than that of subjects in published studies of adult ALL, and 22% of patients were 60 years or older. In a comparative study, outcome was significantly superior with Hyper-CVAD therapy compared with the VAD regimens, in terms of both CR rate and long-term prognosis.The results from small studies suggest that Rituximab confers additional benefits to patient having DA-EPOCH and Hyper-CVAD. Another popular regimen is Codox-M.
Kluin Nelemans H, Zagonel V, Anastasopoulou A et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin’s lymphoma: randomized phase III EORTC study. J Natl Cancer Inst 2001; 93: 22–30K. A. Blum, G. Lozanski, and J. C. Byrd
Adult Burkitt leukemia and lymphoma
Blood, November 15, 2004; 104(10): 3009 – 3020.
S. Smeland, A. K. Blystad, S. O. Kvaloy, I. M. Ikonomou, J. Delabie, G. Kvalheim, J. Hammerstrom, G. F. Lauritzsen, and H. Holte
Treatment of Burkitt’s/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens
Ann. Onc., July 1, 2004; 15(7): 1072 – 1078.
H M. Kantarjian, S. O’Brien, T. L. Smith, J. Cortes, F. J. Giles, M. Beran, S. Pierce, Y. Huh, M. Andreeff, C. Koller, et al.
Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
J. Clin. Oncol., February 1, 2000; 18(3): 547 – 547.